AxoGen Reports Third Quarter 2011 Results

AxoGen, Inc. (OTCBB: AXGN) today reported third quarter of 2011 revenues of $1.1 million, a 42.5% increase over $0.8 million reported during the third quarter of 2010. The higher revenues reflect increased penetration into targeted accounts resulting from the broadening of the Company’s sales and marketing efforts.

In addition, the Company reported a net loss of $3.1 million, or $2.60 per common share, compared to a net loss of $.0.9 million, or $1.05 per common share, reported during the same period in 2010. The pro forma net loss for the quarter as if the merger had taken place on the first day of the period, was $3.0 million, or $0.28 per diluted share, compared to a pro forma net loss of $1.7 million, or $0.15 per diluted share, reported during the same period in 2010.

The reported loss for the period included approximately $643,000 of merger related expenses and $828,000 associated with a one-time, inventory write-off. These items represent $1.11 of the $2.60 loss per common share and $0.13 of the $0.28 pro forma loss per common share.

“I am pleased with our level of execution during this quarter,” stated Karen Zaderej, Chief Executive Officer of AxoGen. “We delivered solid year-over-year, topline growth during a period in which our management team was focused on efforts to complete our merger with LecTec.”

Gross Profit

Gross profit was $10,436 during the period and $1.59 million for the nine months and includes an $828,000 charge related to write-offs associated with expiring inventory and obsolete raw materials. The decrease in gross profit was primarily due to the inventory write-offs with additional contributing factors including a change in product mix and the resumption of manufacturing of Avance ® Nerve Graft in January 2011.

Sales General and Administrative Expenses (SG&A)

Sales, general and administrative expenses (SG&A) increased to $2.0 million during the third quarter of 2011, compared to $1.1 million reported last year and is attributed to the company’s strategic and continued broadening of sales and marketing efforts and approximately $643,000 of merger related expenses.

Ms. Zaderej further commented, “While we are pleased with our topline performance, our merger related efforts impeded sequential growth. With the merger behind us we are now well capitalized and positioned to focus on the execution of our commercialization plan as we move into the fourth quarter.”

Financial Liquidity

At September 30, 2011 the Company had $10.5 million in cash and cash equivalents and $4.8 million in long-term debt.

Merger Accounting

For accounting purposes, AxoGen Corporation was identified as the acquiring entity and AxoGen, Inc. (formerly “LecTec”) as the acquired entity. Accordingly, the condensed consolidated financial statements and related footnote disclosures presented for the period prior to the merger are those of AxoGen Corporation alone. The consolidated financial statements as of September 30, 2011 and December 31, 2010 and for the three months and nine months ended September 30, 2011 and 2010 include the operations and cash flows of AxoGen Corporation through September 30, 2011 and the combined operations and cash flows of AxoGen Corporation and AxoGen, Inc. (“LecTec”) subsequent to the merger. The Consolidated Balance Sheet as of September 30, 2011 includes both companies as of such date.

Earnings Call Information

As previously announced, AxoGen, Inc management will review its third quarter 2011 financials during a conference call scheduled for November 10, 2011 at 3:00 PM Eastern Time. The conference call information is as follows:

Conference dial-in:


International dial-in


Conference ID:



An audio replay of the conference call will be available from 6:00 p.m. ET on November 10, 2011, through 6:00 p.m. ET on November 17, 2011 by dialing 888.203.1112 from the U.S. or 719.457.0820 from abroad. The audio webcast will also be available on the company's website,, for one year.

About AxoGen, Inc.

AxoGen (OTCBB: AXGN) is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes Avance ® Nerve Graft, which AxoGen believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed). AxoGen’s portfolio also includes AxoGuard ® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard ® Nerve Protector that protects nerves during the body’s healing process after surgery. AxoGen is bringing the science of nerve repair to life with over 6,000 surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.

AxoGen (formerly known as LecTec Corporation) is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

AxoGen, Inc.

Condensed Consolidated Statements of Operations

  Three Months Ended   Nine Months Ended
September 30,   September 30, September 30,   September 30,
2011 2010 2011 2010
      (As Restated)

$ 1,140,768 $ 800,743 $ 3,487,824 $ 2,195,812
Cost of goods sold 1,130,332 160,772 1,893,412 536,185
Gross profit 10,436 639,971 1,594,412 1,659,627
Costs and expenses:
Sales and marketing 499,118 320,850 1,318,007 975,839
Research and development 76,982 36,169 117,149 75,452
Salaries, wages and related costs 1,189,289 771,518 2,941,530 2,522,419
General and administrative 827,054 336,038 2,005,740 910,585
Depreciation and amortization   44,427     54,220     191,589     208,502  
Total costs and expenses   2,636,870     1,518,795     6,574,015     4,692,797  
Loss from operations   (2,626,434 )   (878,824 )   (4,979,603 )   (3,033,170 )
Other income (expense):
Interest expense (318,110 ) (193,251 ) (954,360 ) (516,266 )
Interest expense—deferred financing costs (169,007 ) (10,473 ) (1,200,413 ) (134,808 )
Gain from termination of distribution agreement 1,119,094
Change in fair value of warrant liability 139,157 62,305 77,695
Other income (expense)   381     28     (10,163 )   36  
Total other income (expense)  


  (64,539 )   (2,102,631 )   390,361  
Net loss $ (3,113,170 ) $ (943,363 ) $ (7,082,234 ) $ (2,642,809 )
Preferred stock dividends $ (329,832 ) $ (308,944 ) $ (1,028,351 ) $ (3,886,801 )
Net loss available to common shareholders $ (3,443,002 ) $ (1,252,307 ) $ (8,110,585 ) $ (3,886,801 )
Weighted Average Common Shares outstanding – basic and diluted   1,324,967     1,191,000     1,248,798     715,198  
Loss Per Common share - basic and diluted $ (2.60 ) $ (1.05 ) $ (6.49 ) $ (5.43 )
See notes to condensed consolidated financial statements.

AxoGen, Inc.

Condensed Consolidated Balance Sheets
September 30, December 31,
2011 2010
Current assets:
Cash and cash equivalents $ 10,525,537 $ 1,799,048
Accounts receivable 538,109 407,350
Inventory 1,662,343 1,902,789
Prepaid expenses 151,846 66,437
Deferred financing costs   184,995     1,083,630  
Total current assets 13,062,830 5,259,254
Property and equipment, net 293,681 500,742
Goodwill 169,987 -
Intangible assets 906,960 637,771
Other assets   8,000     8,000  
$ 14,441,458   $ 6,405,767  
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable and accrued expenses $ 1,657,113 $ 967,896
Current portion of long-term debt, related party 1,338,455
Current portion of long-term debt       7,080,512  
Total current liabilities 1,657,113 9,386,863
Long-term debt 4,826,264
Preferred stock dividends payable 6,048,378
Warrant liability 2,669,815
Total liabilities   6,483,377     18,105,056  
Commitments and contingencies
Temporary equity:
Series B convertible preferred stock, $.00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding 4,243,948
Series C convertible preferred stock, $.00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding 8,092,568
Series D convertible preferred stock, $.00001 par value; 67,000,000 share authorized; 0 and 30,156,259 shares issued and outstanding 3,075,523
Total temporary equity       15,412,039  
Stockholders’ equity (deficit): 109,498 12,056
Common stock, $.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding
Series A convertible preferred stock, $.00001 par value; 2,544,750 shares authorized, issued and outstanding 1,125,000
Additional paid-in capital 54,142,532 9,934,980
Accumulated deficit (46,293,949 ) (38,183,364 )
Total stockholders’ equity (deficit)   7,958,081     (27,111,328  
$ 14,441,458   $ 6,405,767  
See notes to condensed consolidated financial statements.

Copyright Business Wire 2010

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX